Eterna Operating Income vs Selling General Administrative Analysis
ERNA Stock | USD 0.29 0.03 9.38% |
Eterna Therapeutics financial indicator trend analysis is much more than just examining Eterna Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eterna Therapeutics is a good investment. Please check the relationship between Eterna Therapeutics Operating Income and its Selling General Administrative accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.
Operating Income vs Selling General Administrative
Operating Income vs Selling General Administrative Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eterna Therapeutics Operating Income account and Selling General Administrative. At this time, the significance of the direction appears to have no relationship.
The correlation between Eterna Therapeutics' Operating Income and Selling General Administrative is 0.0. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Eterna Therapeutics, assuming nothing else is changed. The correlation between historical values of Eterna Therapeutics' Operating Income and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Eterna Therapeutics are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Operating Income i.e., Eterna Therapeutics' Operating Income and Selling General Administrative go up and down completely randomly.
Correlation Coefficient | 0.0 |
Relationship Direction | Flat |
Relationship Strength | Insignificant |
Operating Income
Operating Income is the amount of profit realized from Eterna Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Eterna Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Selling General Administrative
Most indicators from Eterna Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eterna Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.The current year's Enterprise Value is expected to grow to about 157.2 M, whereas Tax Provision is forecasted to decline to about 25 K.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 74K | 30K | 614K | 644.7K | Depreciation And Amortization | 459K | 497K | 1.1M | 1.1M |
Eterna Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Eterna Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eterna Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 15.3M | 12.9M | 32.4M | 22.3M | 49.1M | 51.6M | |
Other Current Liab | 1.6M | 966K | 1.1M | 4.0M | 882K | 837.9K | |
Total Current Liabilities | 6.1M | 3.1M | 3.7M | 7.7M | 6.6M | 5.9M | |
Total Stockholder Equity | 5.1M | 7.7M | 6.5M | 12.1M | 2.2M | 2.1M | |
Non Current Assets Total | 9.2M | 11.2M | 13.7M | 8.6M | 39.5M | 41.5M | |
Non Currrent Assets Other | 2.3M | 453K | 522K | 5.2M | 120K | 114K | |
Common Stock Shares Outstanding | 71.9K | 439.7K | 2.2M | 3.1M | 5.3M | 5.0M | |
Liabilities And Stockholders Equity | 15.3M | 12.9M | 32.4M | 22.3M | 49.1M | 51.6M | |
Non Current Liabilities Total | 4.1M | 2.1M | 22.3M | 2.5M | 40.3M | 42.3M | |
Other Current Assets | 526K | 102K | 2.2M | 1.3M | 1.6M | 2.3M | |
Other Stockholder Equity | 136.3M | (245K) | 166.2M | 177.4M | 189.2M | 131.9M | |
Total Liab | 10.2M | 5.2M | 25.9M | 10.2M | 46.9M | 49.2M | |
Total Current Assets | 6.1M | 1.7M | 18.8M | 13.7M | 9.6M | 9.8M | |
Short Long Term Debt Total | 6.1M | 2.9M | 2.7M | 4.1M | 41.8M | 43.9M | |
Property Plant And Equipment Net | 4.7M | 4.9M | 2.7M | 1.3M | 33.3M | 34.9M | |
Current Deferred Revenue | 460K | 76K | 1.2M | 190K | 218.5K | 207.6K | |
Net Debt | 2.8M | 1.3M | (14.3M) | (7.3M) | 34.3M | 36.0M | |
Retained Earnings | (131.5M) | (18.1M) | (159.7M) | (165.3M) | (187.0M) | (196.3M) | |
Accounts Payable | 835K | 1.3M | 1.8M | 1.6M | 1.1M | 764.4K | |
Cash | 3.3M | 1.6M | 17.0M | 11.4M | 7.6M | 6.1M | |
Cash And Short Term Investments | 3.3M | 1.6M | 17.0M | 11.4M | 7.6M | 6.1M | |
Net Receivables | 1.2M | 116K | 684K | 951K | 425K | 678.2K | |
Good Will | 1.0M | 667K | 696K | 2.0M | 2.4M | 1.4M | |
Accumulated Other Comprehensive Income | 200K | 268K | 245K | (1K) | (900.0) | (855.0) | |
Short Term Debt | 3.2M | 799K | 852K | 2.0M | 4.4M | 4.7M | |
Other Liab | 930.4K | 23K | 48K | 1.6M | 1.9M | 2.0M | |
Net Tangible Assets | 7.7M | 5.6M | 23.5M | 10.1M | 11.6M | 12.1M | |
Other Assets | 7.3M | 6.4M | 1K | 5.2M | 4.7M | 4.2M | |
Property Plant Equipment | 653.8K | 2.7M | 3.2M | 1.3M | 1.5M | 1.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eterna Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.